Integer Holdings Corporation
Rank #413ValueITGR · NYSE · Healthcare
Integer Holdings Corporation (ITGR) — Rank #413 by gross profitability (GP/assets 0.15) · ROE 6.0% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001114483 · all metrics point-in-time as of the filing date.
About
Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally.
Show moreShow less
The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016.
Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- integer.net
Price History
Company Snapshot
P/E and dividend yield are the primary valuation lenses for mature businesses.
Market Cap
$4.28B
P/E (annual)
43.7
P/S (annual)
2.3
P/B
2.5
P/OCF (annual)
21.8
Shareholder Yield
0.2%
Employees
11,000
Industry
Medical Devices
Exchange
NYSE
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 1/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
18.0%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -0.2% — per-share value needs a total required return of 17.9% once share-count change is priced in.
vs. own 6-year median revenue growth: 11.5%
priced above its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
13.1%
r = 10% (base)
18.0%
r = 12%
22.3%
Net debt / market cap: 27.1%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).
Profitability
Gross profitability (GP / assets)
0.15
Primary signal (Novy-Marx).
0th pctl of 37 SIC 38 peers
Return on equity
6.0%
Gross margin
27.0%
6th pctl of 37 SIC 38 peers
Revenue growth (YoY)
8.0%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
11.7%
Revenue CAGR (5Y)
11.5%
Earnings CAGR (3Y)
15.7%
FCF CAGR (3Y)
36.1%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.99
47th pctl of 35 SIC 38 peers (best = lowest)
Current ratio
3.73×
77th pctl of 36 SIC 38 peers
Quick ratio
1.66×
Net cash
-$1.22B
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$105.12M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
0.02
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.3%
Stock-based comp intensity.
Piotroski F-Score
F-Score
6 / 9
Fundamental-strength score (0-9).